Oncology - MarketMinute (Page 2)

Merit Medical Systems

Merit Medical Systems' SCOUT Technology Reaches Milestone, New SCOUT MD™ System Poised to Reshape Surgical Precision

Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT Radar Localization technology, which has now been utilized in over 750,000 patient procedures worldwide. This achievement, coinciding with Breast Cancer Awareness Month, underscores the widespread adoption and critical impact of the wire-free, non-radioactive localization device in

FDA Approval

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca (lurbinectedin) and Roche's (SIX: ROG, OTCQX: RHHBY) Tecentriq (atezolizumab), along with its subcutaneous formulation Tecentriq Hybreza. This

Nanobiotix

Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes

Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed

Merus N.V.

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0

Eli Lilly

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a substantial increase from an initial plan of $2.148 billion, marks a pivotal moment in Lilly's strategy to bolster its

Oncology

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca (pirtobrutinib). Olomorasib recently secured a coveted Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for